Paper Title
IN SILICO ANALYSIS OF HIV DRUG (NRTI EQ: ABACAVIR) IN ALZHEIMER’S PATIENTS

Abstract
Abstract - Since the discovery of the unit of life-cell we have been presuming that every single cell has the same blueprint, where a skin cell is capable of producing insulin but evolves to do the particular function. However, the blueprint never changes but the recent research contradicts the argument by stating that it is not the scenario for neurons (brain), in due course it goes through recombination which further creates gene variants in the brain leading to never ever seen before variation in brain. An enzyme reverse transcriptase reinserts new codons to the DNA blueprint creating a new unit that can enhance our brain or the toxic unit (deleterious) that can confuse the brain, via performing wet lab experiments in 2018, scientists linked this enhancement with the case of Alzheimer’s. Where they tested the theory on mouse lines (added NTRI’s) and the procedure showed that there’s some kind of modification occurring which stopped the possible somatic recombination. Giving us the idea that after years of research on finding out the treatment, an already FDA approved medication could possibly be the cure: stating that the HIV NTRI’s medicines holds potential of treating Alzheimer’s. In steps to reach an understanding through our research study we have found that many NTRI’s like abacavir (Ziagen), Emtricitabine (Emtriva), Lamivudine (Epivir) could easily surpass the blood brain barrier and abacavir also had a good binding affinity towards our target protein i.e. amyloid precursor protein with about 6 Hydrophobic interactions, 3 Hydrogen bonds which was simulated via gromacs and was able to survive the condition. Keywords - Drug repurposing, HIV, NTRI’s, Alzheimer’s